Press Release

Regulated information



IBA to Install Proton Therapy Center in Virginia, USA

Contract signed with Inova Health Care Services for two-room Proteus®PLUS* proton therapy system near IBA's North American Headquarters

Reston, VA, USA, July 5th, 2017 – IBA (Ion Beam Applications S.A.), the world's leading provider of proton therapy solutions for the treatment of cancer, and Inova Health Care Services (Inova) today signed a contract for a two-room Proteus®PLUS* proton therapy solution, each treatment room equipped with Pencil Beam Scanning capability and integrated Cone Beam CT.

The total value of the equipment and services supplied by IBA to Inova is approximately \$60M. The project is fully financed and includes a long-term operation and maintenance contract. Inova plans to start treating patients by 2020.

Olivier Legrain, Chief Executive Officer of IBA SA, commented: "We are pleased to announce that Inova has selected IBA as its proton therapy partner. IBA's proton therapy technology has been used to treat more cancer patients than any other proton therapy company in the world and we look forward to bringing this powerful cancer treatment tool to the patient community of Northern Virginia and beyond."

Beth Klein, President of IBA North America, added: "Inova's proton therapy project is unique in that it is located only 15 miles from IBA's North America Headquarters in Reston, Virginia, where we have the largest and most comprehensive Proton therapy support structure in the industry. Having the Inova center located near our North American office will facilitate collaboration with them as we work together to advance the use of proton therapy for those patients and families impacted by this devastating disease."

"The addition of proton therapy to our oncology services, will allow Inova to build upon our already strong local, national and international oncology services reach by providing one of the most significant technology innovations in the treatment of Cancer," added Thomas Graves, Vice President for Cancer Services and Associate Director for Administration of the Inova Dwight and Martha Schar Cancer Institute. "The Center will be housed at Inova's Center for Personalized Health, offering patients easy access from anywhere in Virginia and the Metro DC area. This advanced technology will be an excellent complement to the best in class oncology services we will be offering at the facility."

Dr. Gopal Bajaj, Chairman and Medical Director of Radiation Oncology at Inova Dwight and Martha Schar Cancer Institute, added: "Being able to provide such a powerful cancer treatment truly puts Inova's radiation oncology department at the forefront of cancer treatment delivery. Proton therapy is an exciting alternative to traditional radiation treatment protocols, allowing us to treat many cancer patients more effectively, and often without the uncomfortable side effects that traditional treatments may cause. This technology will have a very positive impact on the thousands of people in our community who are touched by cancer."

ENDS

PROTECT + ENHANCE +

1

Press Release

Regulated information



About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the Pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

*Proteus®PLUS is the brand name of a configuration of the Proteus®235

About Inova

Inova is a global leader in personalized health, which leverages precision medicine to predict, prevent and treat disease, enabling individuals to live longer, healthier lives. Inova serves more than 2 million people each year throughout the Washington, DC, metro area and beyond. Inova's five hospitals include more than 1,700 licensed beds and 16,000 employees. Inova encompasses the full array of health services, including the area's only Level 1 Trauma Center and Level IV neonatal intensive care unit. Inova is also home to nationally and internationally recognized Inova Heart and Vascular Institute (IHVI), Inova Translational Medicine Institute (ITMI) focused on genomics research, Inova Neuroscience Institute, Inova Children's Hospital and Inova Schar Cancer Institute soon to include proton therapy.



Press Release

Regulated information



For further information, please contact:

IBA

Soumya Chandramouli

Chief Financial Officer

Bernard Dandoy

Investor Relations +32 10 475 890

Investorrelations@iba-group.com

Thomas Ralet

Vice-President Corporate Communication +32 10 475 890 communication@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications

Amber Fennell, Matthew Neal, Ivar Milligan +44 (0) 20 3709 5700

IBA@consilium-comms.com

